Levasure 7.5% w/v Oral Solution

Pajjiż: Ingilterra

Lingwa: Ingliż

Sors: VMD (Veterinary Medicines Directorate)

Ingredjent attiv:

Levamisole Hydrochloride

Disponibbli minn:

Chanelle Pharmaceuticals Manufacturing Ltd

Kodiċi ATC:

QP52AE01

INN (Isem Internazzjonali):

Levamisole Hydrochloride

Għamla farmaċewtika:

Oral solution

Tip ta 'preskrizzjoni:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

Grupp terapewtiku:

Cattle, Sheep

Żona terapewtika:

Anthelmintic

L-istatus ta 'awtorizzazzjoni:

Authorized

Data ta 'l-awtorizzazzjoni:

2002-03-13

Karatteristiċi tal-prodott

Revised: July 2013
AN: 00263/2013
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Levasure 7.5% w/v Oral Solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Constituents
Levamisole HCl
Excipients
Sodium Metabisulphite
Tartrazine E102
7.5% w/v
0.1% w/v
0.00375% w/v
For a full list of excipients see Section 6.1
3.
PHARMACEUTICAL FORM
Oral Solution
A yellow coloured clear solution
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle, Sheep.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Levasure 7.5% w/v Oral Solution is a broad spectrum anthelmintic for
the
treatment and control of gastro-intestinal and pulmonary nematode
infections in
cattle and sheep.
Levasure 7.5% w/v Oral Solution is effective against mature and
developing
immature stages of the following levamisole-susceptible major nematode
worm
species:-
GASTRO-INTESTINAL WORMS: _Trichostrongylus _spp.,_ Cooperia _spp.,
_Ostertagia_ spp.
(except inhibited Ostertagia larvae in cattle), _Haemonchus _ spp.,
_Nematodirus _
spp.,
_Bunostomum _ spp., _Oesophagostomum _spp., _Chabertia _spp.
LUNGWORMS: _Dictyocaulus_ spp.
Levasure 7.5% w/v Oral Solution is not effective against Type II
winter scour.
Revised: July 2013
AN: 00263/2013
Page 2 of 6
4.3
CONTRAINDICATIONS
Animals should not be treated simultaneously or within 14 days before
or after the
use of Levasure 7.5% w/v Oral Solution with organophosphorous
compounds or
diethylcarbamazine citrate.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they
increase the
risk of development of resistance and could ultimately result in
ineffective therapy:
● Too frequent and repeated use of anthelmintics from the same
class, over
an extended period of time.
● Underdosing, which may be due to underestimation of bodyweight,
misadministration of the product, or lack of calibration of the dosing
device
(if any).
Suspected clinical cases of resistance to anthelmintics should be
further
investigated using appropr